SLC9A1 and endothelial dysfunction: Focusing on reviewing the recent patent literature and related preclinical supporting evidence, as well as some ongoing clinical trials, antioxidant polyphenol-rich extracts, the synthetic thromboxane inhibitor ramatroban, and other synthetic small-molecule drugs like emricasan (a pan-caspase inhibitor) and rimeporide (an NHE-1 inhibitor) emerged as candidates for the treatment of endothelial dysfunction, anomalous blood clotting, and oxidative stress underlying COVID-related cardiovascular pathologies.